Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation plus immune therapy shows promise for hard-to-treat lymphoma

NCT ID NCT07528352

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated Jun 13, 2026 · Updated 12 times

Summary

This early-phase study tests whether giving radiation therapy before a bispecific antibody (epcoritamab or glofitamab) is safe for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. The main goal is to check for serious side effects like cytokine release syndrome and nerve toxicity. Up to 12 adults will receive radiation to up to 3 tumors followed by the antibody therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute at University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA